Product Center
  • Trabectome

  • MIGS new technique
    The first line Glaucoma surgery in US and EU


    Product Characteristics:
    1. Micro Invasion:1.8mm cornea incision、no invasion to conjunctiva and sclera
    2. Longer treatment affection:IOP decreasing 40% post-op
       Medications decreasing 25%~43% post-op
       Stable IOP and medications after 90 months follow-up
    3. Safty:Lowest side-effect and complication post-op
       No implant and related risk
       No filtering bleb, and no affected other filtering surgery









National after-sales service hotline

400-888-0559

E-mali:

info@gaush.com

Gaush Medical Wechat Public Account